Currently browsing tag

headquarters

Roche receives blood cancer drug blow after Gazyva trial fails to meet endpoint

Swiss drugmaker Roche said trials showed its new blood cancer drug Gazyva failed to deliver significant improvements over an older medicine in people with an aggressive type of blood cancer, a blow in its fight against competition from biosimilars. Gazyva did not significantly reduce the risk of disease worsening or death for people with previously untreated diffuse large B-cell lymphoma, over current drug Rituxan in a phase III GOYA study, Roche said on Monday. Diffuse large B-cell lymphoma is the most common form of non-Hodgkin's lymphoma.

Valeant gets notice of default from bondholders

(Reuters) – Beleaguered Canadian drugmaker Valeant Pharmaceuticals International Inc said it received a notice of default from bondholders for the delay in filing its first-quarter report. Last week, Valeant had said it expected to file the report with U.S. and Canadian regulators on or before June 10, ahead of a July 31 deadline. Valeant had been one of the pharmaceutical industry's most widely owned stocks as its steady stream of acquisitions fueled strong gains in its shares.

Pfizer hikes U.S. prices for over 100 drugs on January 1

Pfizer Inc , which plans a $160-billion merger with Ireland-based Allergan Plc to slash its U.S. tax bill, on Jan. 1 raised U.S. prices for more than 100 of its drugs, some by as much as 20 percent, according to statistics compiled by global information services company Wolters Kluwer. Company spokesman Steven Danehy could not immediately confirm the remaining price increases, which were compiled by a unit of Wolters Kluwer Health and published in a research note by UBS Securities.